Serious adverse drug reactions associated with<unk>  therapy include: * Thrombotic thrombocytopenic purpura (incidence: four per million patients treated) * Hemorrhage – the annual incidence of hemorrhage may be increased by the coadministration of aspirin. In the CURE trial, people with acute coronary syndrome without ST elevation were treated with aspirin plus<unk>  or placebo and followed for up to one year. The following rates of major bleed were seen: * Any major bleeding:<unk>  3.7%, placebo 2.7% * Life-threatening bleeding:<unk>  2.2%, placebo 1.8% * Hemorrhagic stroke:<unk>  0.1%, placebo 0.1% The CAPRIE trial compared<unk>  monotherapy to aspirin monotherapy for 1.6 years in people who had recently experienced a stroke or heart attack. In this trial the following rates of bleeding were observed. * Gastrointestinal hemorrhage:<unk>  2.0%, aspirin 2.7% * Intracranial bleeding:<unk>  0.4%, aspirin 0.5% In CAPRIE, itching was the only adverse effect seen more frequently with<unk>  than aspirin. In CURE, there was no difference in the rate of non-bleeding adverse events. Rashes and itching were uncommon in studies (between 0.1 and 1% of people); serious hypersensitivity reactions are rare.
Clopidogrel
Ticlopidine
Ticagrelor
Prokarin
Apixaban
Rivaroxaban
Warfarin
Heparin